Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Gilead Says It Has No Intention to Scrap License Deal: Carna Bio
Kobe-based biotech Carna Biosciences said on September 9 that it has received confirmation from Gilead Sciences that the US firm has no intention at this time of ending their licensing agreement related to a drug discovery program for DGKα inhibitors.…
To read the full story
BUSINESS
- Kazuo Nakamura, Founder of Japan’s First CRO, Dies at 78
December 9, 2025
- Erbitux-Braftovi Combo Now Available for Frontline BRAF-Mutant Colorectal Cancer in Japan
December 9, 2025
- Limited Sites, Bed Capacity Seen as Key Hurdles to Radioligand Therapy Uptake: Urologist
December 8, 2025
- Retevmo Now Available in Tablet Form: Lilly Japan
December 8, 2025
- Japan Ethical Drug Sales Rise 5.9% in October: Crecon
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…